Almirall Year in review 2023 ES (11/44)

Almirall Year in review 2023 ESAlmirall Year in review 2023 ES (11/44)Almirall Year in review 2023 ES - (1/44)Almirall Year in review 2023 ES - (2/44)Almirall Year in review 2023 ES - (3/44)Almirall Year in review 2023 ES - (4/44)Almirall Year in review 2023 ES - (5/44)Almirall Year in review 2023 ES - (6/44)Almirall Year in review 2023 ES - (7/44)Almirall Year in review 2023 ES - (8/44)Almirall Year in review 2023 ES - (9/44)Almirall Year in review 2023 ES - (10/44)Almirall Year in review 2023 ES - (11/44)Almirall Year in review 2023 ES - (12/44)Almirall Year in review 2023 ES - (13/44)Almirall Year in review 2023 ES - (14/44)Almirall Year in review 2023 ES - (15/44)Almirall Year in review 2023 ES - (16/44)Almirall Year in review 2023 ES - (17/44)Almirall Year in review 2023 ES - (18/44)Almirall Year in review 2023 ES - (19/44)Almirall Year in review 2023 ES - (20/44)Almirall Year in review 2023 ES - (21/44)Almirall Year in review 2023 ES - (22/44)Almirall Year in review 2023 ES - (23/44)Almirall Year in review 2023 ES - (24/44)Almirall Year in review 2023 ES - (25/44)Almirall Year in review 2023 ES - (26/44)Almirall Year in review 2023 ES - (27/44)Almirall Year in review 2023 ES - (28/44)Almirall Year in review 2023 ES - (29/44)Almirall Year in review 2023 ES - (30/44)Almirall Year in review 2023 ES - (31/44)Almirall Year in review 2023 ES - (32/44)Almirall Year in review 2023 ES - (33/44)Almirall Year in review 2023 ES - (34/44)Almirall Year in review 2023 ES - (35/44)Almirall Year in review 2023 ES - (36/44)Almirall Year in review 2023 ES - (37/44)Almirall Year in review 2023 ES - (38/44)Almirall Year in review 2023 ES - (39/44)Almirall Year in review 2023 ES - (40/44)Almirall Year in review 2023 ES - (41/44)Almirall Year in review 2023 ES - (42/44)Almirall Year in review 2023 ES - (43/44)Almirall Year in review 2023 ES - (44/44) Almirall en cifras, 2023 1 El número total incluye Klisyri® (tirbanibulina), Ilumetri® (tildrakizumab), Wynzora® (calcipotriol/betametasona) y Seysara® (sareciclina) en 2023. Los y las pacientes, nuestra prioridad EBITDA 174.1 M€ Crecimiento de Ventas Netas +4% interanual Ventas netas 894.5 M€ Número de productos Productos dermatológicos Personas a las que hemos ayudado con nuestros productos dermatológicos clave 1 Resto del mundo 3% Ventas Netas en dermatología por geografía Europa 85% EE.UU 12% Ventas Netas en dermatología 465.2 M€ 52.0% Del total de ventas +8% interanual 628,181 143 51